Ranked #1,677 of 8,699 institutional investors
Caligan Partners LP
New York, NY
$1.71B
US stock portfolio at live prices · today −$8.0M (−0.46%)
Market closed. Prices as of Nov 20, 9:11 AM ET
- Value at quarter end (Q3 2026)
- $1.63B
- Change from Q2 2026
- −$438.6M (−21.16%)
- Positions
- 25 · 2 new, 2 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$2.5M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesLQDA 26.9%RVMD 18.3%PCVX 7.47%ABVX 7.35%EXEL 5.98%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| LQDA Liquidia Corporation | 8,118,892 | $460M | 26.9% | Unchanged |
| RVMD Revolution Medicines, Inc. | 1,961,795 | $313M | 18.3% | Unchanged |
| PCVX Vaxcyte, Inc. | 2,188,636 | $128M | 7.47% | Unchanged |
| ABVX ABIVAX Société Anonyme | 1,557,924 | $126M | 7.35% | Unchanged |
| EXEL Exelixis, Inc. | 1,553,262 | $102M | 5.98% | Unchanged |
| ADMA ADMA Biologics, Inc. | 5,875,007 | $78.4M | 4.59% | Added +3% |
| VRDN Viridian Therapeutics, Inc. | 2,193,981 | $69.0M | 4.04% | Unchanged |
| LBRX LB Pharmaceuticals Inc | 1,509,621 | $60.4M | 3.54% | Added +5% |
| TNGX Tango Therapeutics, Inc. | 2,501,246 | $56.8M | 3.32% | Unchanged |
| IMCR Immunocore Holdings plc | 1,672,141 | $44.5M | 2.61% | Added +21% |
| VOR Vor Biopharma Inc. | 1,925,066 | $35.7M | 2.09% | Unchanged |
| AURA Aura Biosciences, Inc. | 4,590,253 | $32.0M | 1.87% | Added +7% |
| IVA Inventiva S.A. | 9,185,935 | $31.7M | 1.85% | Added +13% |
| SGMT Sagimet Biosciences Inc. | 2,794,484 | $26.9M | 1.57% | Added +12% |
| SABS SAB Biotherapeutics, Inc. | 8,736,898 | $25.4M | 1.49% | Added +10% |
| IRD Opus Genetics, Inc. | 5,960,972 | $24.3M | 1.42% | Reduced −2% |
| AVTX Avalo Therapeutics, Inc. | 3,268,303 | $22.1M | 1.29% | Added +3% |
| ANIK Anika Therapeutics, Inc. | 1,435,130 | $19.1M | 1.12% | Unchanged |
| TYRA Tyra Biosciences, Inc. | 910,749 | $18.0M | 1.05% | Added +13% |
| OBX Obsidian Therapeutics, Inc. | 886,281 | $10.8M | 0.63% | New |
| FTH Faeth Therapeutics, Inc. | 890,210 | $7.7M | 0.45% | Added +41% |
| EPRX Eupraxia Pharmaceuticals Inc. | 1,163,010 | $7.1M | 0.42% | New |
| ARTV Artiva Biotherapeutics, Inc. | 1,481,043 | $5.7M | 0.33% | Reduced −15% |
| VRCA Verrica Pharmaceuticals Inc. | 923,910 | $2.7M | 0.16% | Unchanged |
| CLRB Cellectar Biosciences, Inc. | 469,998 | $415K | <0.1% | Unchanged |